To harness its anti-tumor therapeutic potential and enhance clinical applicability, various bioengineering strategies are being actively explored, with PEGylation serving as a key advancement in improving IL-10’s stability, half-life, and pharmacokinetics. This evidence concerns the gene IL10 and neoplasm.